Dean A Fennell

Summary

Country: UK

Publications

  1. ncbi Advances in the systemic therapy of malignant pleural mesothelioma
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
    Nat Clin Pract Oncol 5:136-47. 2008
  2. ncbi BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
    Sara Busacca
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Northern Ireland, UK
    J Pathol 227:200-8. 2012
  3. ncbi Ultra-fast processing of gigapixel Tissue MicroArray images using High Performance Computing
    Yinhai Wang
    Centre for Biomedical Informatics, Queen s University Belfast, Health Science Building, 97 Lisburn Road, Belfast, BT9 7BL, UK
    Cell Oncol (Dordr) 34:495-507. 2011
  4. ncbi Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression
    Hiu Fung Yuen
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, UK
    Cancer Sci 103:1145-54. 2012
  5. ncbi PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer
    Ian Paul
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, UK
    J Pathol 224:564-74. 2011
  6. ncbi A TMA de-arraying method for high throughput biomarker discovery in tissue research
    Yinhai Wang
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, United Kingdom
    PLoS ONE 6:e26007. 2011
  7. ncbi Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
    Jaine K Blayney
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Northern Ireland, UK
    Eur J Cancer 48:2983-92. 2012
  8. ncbi Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
    Jane L Hurwitz
    Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen s University Belfast, Northern Ireland, UK
    Eur J Cancer 48:1096-107. 2012
  9. ncbi Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition
    Hiu Fung Yuen
    Centre for Cancer Research and Cell Biology, Queen s University of Belfast, UK
    J Pathol 224:78-89. 2011
  10. ncbi Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
    Francois Fay
    Molecular Therapeutics, School of Pharmacy, Queen s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
    Biomaterials 32:8645-53. 2011

Collaborators

Detail Information

Publications25

  1. ncbi Advances in the systemic therapy of malignant pleural mesothelioma
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Liburn Road, Belfast BT9 7BL, Northern Ireland, UK
    Nat Clin Pract Oncol 5:136-47. 2008
    ..Coupled with high-quality translational research, such developments have real potential to improve the outlook of patients at a time of increasing incidence...
  2. ncbi BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
    Sara Busacca
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Northern Ireland, UK
    J Pathol 227:200-8. 2012
    ..9% of samples. Together, these data suggest that BRCA1 plays a critical role in mediating apoptosis by vinorelbine in mesothelioma, warranting its clinical evaluation as a predictive biomarker...
  3. ncbi Ultra-fast processing of gigapixel Tissue MicroArray images using High Performance Computing
    Yinhai Wang
    Centre for Biomedical Informatics, Queen s University Belfast, Health Science Building, 97 Lisburn Road, Belfast, BT9 7BL, UK
    Cell Oncol (Dordr) 34:495-507. 2011
    ..The digitised TMA slides or TMA Virtual Slides, are ultra-large digital images, and can contain several hundred samples. The processing of such slides is time-consuming, bottlenecking a potentially high throughput platform...
  4. ncbi Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression
    Hiu Fung Yuen
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, UK
    Cancer Sci 103:1145-54. 2012
    ..Our results strongly suggest that BMP6, noggin and SOST could be used in combination as a prognostic indicator in cancer progression...
  5. ncbi PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer
    Ian Paul
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, UK
    J Pathol 224:564-74. 2011
    ....
  6. ncbi A TMA de-arraying method for high throughput biomarker discovery in tissue research
    Yinhai Wang
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast, United Kingdom
    PLoS ONE 6:e26007. 2011
    ..These factors demand the development of a robust method for de-arraying TMAs which identifies each TMA core, and assigns them to their appropriate coordinates on the constructed TMA slide...
  7. ncbi Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
    Jaine K Blayney
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Northern Ireland, UK
    Eur J Cancer 48:2983-92. 2012
    ..We also validate published progression-free survival rates (PFSRs) and a progression-free survival (PFS) prognostic-index model...
  8. ncbi Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
    Jane L Hurwitz
    Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen s University Belfast, Northern Ireland, UK
    Eur J Cancer 48:1096-107. 2012
    ..The histone deacetylase (HDAC) inhibitor Vorinostat (SAHA) is currently being evaluated in relapsed mesothelioma. We examined the roles of FLIP and caspase 8 in regulating SAHA-induced apoptosis in MPM...
  9. ncbi Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition
    Hiu Fung Yuen
    Centre for Cancer Research and Cell Biology, Queen s University of Belfast, UK
    J Pathol 224:78-89. 2011
    ..In conclusion, our results suggest that Pea3 may be an important prognostic marker and a therapeutic target for metastatic progression of human breast cancer...
  10. ncbi Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
    Francois Fay
    Molecular Therapeutics, School of Pharmacy, Queen s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK
    Biomaterials 32:8645-53. 2011
    ..These results demonstrate that antibodies on nanoparticulate surfaces can be exploited for dual modes of action to enhance the therapeutic utility of the modality...
  11. ncbi Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer
    Claire Grills
    Centre for Biomedical Informatics, Queen s University Belfast, Belfast, Northern Ireland, United Kingdom
    PLoS ONE 6:e14635. 2011
    ..To test this hypothesis, we conducted an in vivo gene-expression meta-analysis of surgically resected non-small cell lung cancer (NSCLC) using 602 individual expression profiles, to examine the impact of VDAC1 on survival...
  12. ncbi Ultra-fast processing of gigapixel Tissue MicroArray images using high performance computing
    Yinhai Wang
    Centre for Biomedical Informatics, Queen s University Belfast, Belfast, UK
    Anal Cell Pathol (Amst) 33:271-85. 2010
    ..The digitised TMA slides or TMA Virtual Slides, are ultra-large digital images, and can contain several hundred samples. The processing of such slides is time-consuming, bottlenecking a potentially high throughput platform...
  13. ncbi Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis
    Nyree Crawford
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, UK
    Apoptosis 16:311-20. 2011
    ..Conservation of sensitivity to BH3 domain induced apoptosis can be exploited by agents such as obatoclax, which directly target the mitochondria and BCL-2 family...
  14. ncbi New advances in the second-line treatment of small cell lung cancer
    Jane L Hurwitz
    Centre for Cancer Research and Cell Biology, Queen s University Belfast, Belfast BT9 7BL, Northern Ireland
    Oncologist 14:986-94. 2009
    ..Several Bcl-2 inhibitors, including obatoclax, are currently entering clinical trials in SCLC and are an exciting area of drug development in the relapsed setting...
  15. ncbi Molecular and Immunological approaches
    Dean A Fennell
    Centre for Cancer Research and Cell Biology, Queen's University, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
    Lung Cancer 49:S87. 2005
  16. ncbi Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation
    Dean A Fennell
    Thoracic Oncology Research Group, Centre for Cancer Research and Cell Biology, Oncology, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland
    Clin Cancer Res 11:2097-105. 2005
    ..This review discusses current knowledge relating to caspase regulation in NSCLC and highlights novel strategies for reversing the apoptosis resistant phenotype, with potential to accelerate development of effective therapy...
  17. ncbi In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
    Peter W Szlosarek
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, UK
    Clin Cancer Res 12:7126-31. 2006
    ..A phase II clinical trial is planned to evaluate the role of arginine depletion in patients with AS-negative MPM...
  18. ncbi Prognostic factors in mesothelioma
    Jeremy P C Steele
    Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital and Medical College, London EC1A 7BE, UK
    Lung Cancer 49:S49-52. 2005
    ..9 months [95% C.I.=8.5-11.3] for those in the worst group. The suggestion is that all clinical and biological factors relevant to prognosis should be recorded prospectively in mesothelioma patients selected for clinical trials...
  19. ncbi Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials
    Dean A Fennell
    Lung Cancer and Mesthelioma Unit, Department of Oncology, and the Institute of Cell and Molecular Science Pathology, St Bartholomew s Hospital, London, United Kingdom
    J Clin Oncol 23:184-9. 2005
    ..Our retrospective analysis set out to test the validity of the model as a prognostic tool in patients treated in three phase II trials at St Bartholomew's Hospital (London, United Kingdom) between 1999 and 2003...
  20. ncbi Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
    Dean A Fennell
    Department of Medical Oncology, Lung Cancer and Mesothelioma Research Group, St Bartholomew s Hospital, West Smithfield, London, UK
    Lancet Oncol 5:354-62. 2004
    ..This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer...
  21. ncbi Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London, UK
    Cancer 109:93-9. 2007
    ..Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor...
  22. ncbi Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma
    Andrea Sartore Bianchi
    Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1 27100 Pavia corrected Italy
    Clin Cancer Res 13:5942-51. 2007
    ..We aimed at verifying whether the proteasome inhibitor Bortezomib could abrogate NF-kappaB activity in MMe cells, leading to tumor cell death and may be established as a novel treatment for this aggressive neoplasm...
  23. ncbi Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
    Dean A Fennell
    Lung and Mesothelioma Unit, Department of Medical Oncology, St Bartholomew s Hospital, West Smithfield, London EC1A 7BE, United Kingdom
    Lung Cancer 47:277-81. 2005
    ..CONCLUSION: VO has activity in MPM with most patients responding or having stable disease, although this doublet is associated with significant toxicity...
  24. ncbi Pulmonary toxicity and cancer treatment
    Dean A Fennell
    Lung Cancer and Mesothelioma Research Group, Department of Medical Oncology, St Bartholomew's Hospital, London
    Hosp Med 65:462-5. 2004
    ..This article discusses the mechanisms, common clinical features and risk factors for cytotoxic drug-induced pulmonary toxicity, and outlines general management principles...
  25. ncbi PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism
    Deborah E Banker
    Clinical Research Division, FHCRC, D1 100, 1124 Columbia Street, Seattle, WA 98104, USA
    Leuk Res 26:91-106. 2002
    ..Therefore, PK11195 might contribute to improved clinical outcomes in AML...